StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

Stock analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Stock Performance

NERV opened at $2.17 on Tuesday. The stock’s 50 day moving average price is $2.22 and its 200-day moving average price is $2.58. Minerva Neurosciences has a one year low of $2.06 and a one year high of $13.49. The stock has a market cap of $15.13 million, a price-to-earnings ratio of -4.92 and a beta of 0.11.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.